Keyphrases
Tenofovir
100%
Combination Microbicide
100%
Vaginal Gel
100%
UC781
100%
In Vitro Release
42%
Tissue Concentration
28%
Bolus
28%
Microbicides
28%
Tissue Model
28%
Tumor Retention
28%
Histology
14%
Order of Magnitude
14%
Release Rate
14%
Interleukin-1β
14%
Ex Vivo Tissues
14%
Vaginal Tissue
14%
Interleukin-8
14%
Organotypic
14%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
14%
Electrical Resistance
14%
Rheological Properties
14%
Once-daily Dosing
14%
Tissue Viability
14%
In Vitro Release Rate
14%
Half Maximal Inhibitory Concentration
14%
Gel Type
14%
Gel Viscosity
14%
Micronized
14%
In Vivo Pharmacokinetics
14%
Mixture Experiments
14%
Gel Composition
14%
Tissue Safety
14%
Pharmacology, Toxicology and Pharmaceutical Science
Tenofovir
100%
N [4 Chloro 3 (3 Methyl 2 Butenyloxy)phenyl] 2 Methyl 3 Furancarbothioamide
100%
Antimicrobial Agent
100%
Leporidae
28%
Drug Release
14%
Cytokine
14%
Interleukin 1beta
14%
Nonnucleoside Reverse Transcriptase Inhibitor
14%
Interleukin 8
14%
IC50
14%
Pharmacokinetics
14%